141 related articles for article (PubMed ID: 1954984)
1. A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients.
Shimamoto Y; Anami Y; Yamaguchi M
Eur J Haematol; 1991 Oct; 47(4):262-7. PubMed ID: 1954984
[TBL] [Abstract][Full Text] [Related]
2. IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients.
Shimamoto Y
Cancer Detect Prev; 1995; 19(5):426-35. PubMed ID: 7585729
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin D myeloma--problems with diagnosing and staging (own experience and literature review).
Kuliszkiewicz-Janus M; Zimny A; Sokolska V; Saşiadek M; Kuliczkowski K
Leuk Lymphoma; 2005 Jul; 46(7):1029-37. PubMed ID: 16019554
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival in a case of high-risk type IgD myeloma; a possibility of effectiveness of interferon-alpha and erythropoietin.
Hiyoshi M; Hashimoto S; Ota T; Nakao T; Takubo T; Tagawa S; Tatsumi N
Haematologia (Budap); 1997; 28(3):177-80. PubMed ID: 9283919
[TBL] [Abstract][Full Text] [Related]
5. IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay.
Djidjik R; Lounici Y; Chergeulaïne K; Berkouk Y; Mouhoub S; Chaib S; Belhani M; Ghaffor M
Pathol Biol (Paris); 2015 Sep; 63(4-5):210-4. PubMed ID: 26294067
[TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents.
Zagouri F; Kastritis E; Symeonidis AS; Giannakoulas N; Katodritou E; Delimpasi S; Repousis P; Terpos E; Dimopoulos MA;
Eur J Haematol; 2014 Apr; 92(4):308-12. PubMed ID: 24460646
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in IgD myeloma: a study of 21 cases.
Fibbe WE; Jansen J
Scand J Haematol; 1984 Nov; 33(5):471-5. PubMed ID: 6515330
[TBL] [Abstract][Full Text] [Related]
8. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
[TBL] [Abstract][Full Text] [Related]
9. Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.
Chong YP; Kim S; Ko OB; Koo JE; Lee D; Park SH; Park SJ; Lee D; Kim SW; Suh C
J Korean Med Sci; 2008 Oct; 23(5):819-24. PubMed ID: 18955788
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Morris C; Iacobelli S; Gahrton G; van Biezen A; Drake M; Garderet L; Potter M; Schattenberg AV; Cornelissen JJ; Hamladji RM; Martelli M; Petersen E; Rovira M; Bandini G; Kroger N; de Witte T
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1054-8. PubMed ID: 25708221
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.
Agbuduwe C; Iqbal G; Cairns D; Menzies T; Dunn J; Gregory W; Kaiser M; Owen R; Pawlyn C; Child JA; Davies F; Morgan GJ; Jackson GH; Drayson MT; Basu S
Blood Adv; 2022 Sep; 6(17):5113-5123. PubMed ID: 35790108
[TBL] [Abstract][Full Text] [Related]
12. N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma.
Chen J; Fang M; Chen X; Yi C; Ji J; Cheng C; Wang M; Gu X; Sun Q; Gao C
BMC Cancer; 2017 Dec; 17(1):881. PubMed ID: 29268706
[TBL] [Abstract][Full Text] [Related]
13. IgD myeloma: clinical, biological and laboratory features.
Sinclair D
Clin Lab; 2002; 48(11-12):617-22. PubMed ID: 12465746
[TBL] [Abstract][Full Text] [Related]
14. [Clinical Characteristics and Survival Analysis of Patients with IgD Multiple Myeloma].
Gao XY; Ma YP; Chao Y; Fan L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):547-552. PubMed ID: 33812429
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and outcome of autologous transplantation in rare myelomas.
Morris C; Drake M; Apperley J; Iacobelli S; van Biezen A; Bjorkstrand B; Goldschmidt H; Harousseau JL; Morgan G; de Witte T; Niederwieser D; Gahrton G;
Haematologica; 2010 Dec; 95(12):2126-33. PubMed ID: 20971818
[TBL] [Abstract][Full Text] [Related]
16. Renal involvement in IgD myeloma.
Bergesio F; Salvadori M; Lombardi M; Michelassi S; Salerno A; Monzani G; Florian A; Imreh F; Guidi S
Scand J Urol Nephrol; 1988; 22(4):309-12. PubMed ID: 3238338
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases.
Bladé J; Lust JA; Kyle RA
J Clin Oncol; 1994 Nov; 12(11):2398-404. PubMed ID: 7964956
[TBL] [Abstract][Full Text] [Related]
18. Comparison among immunologically different subtypes of 595 untreated multiple myeloma patients in northern China.
Zhang L; Qi JY; Qi PJ; Wang YF; Zou DH; Yao HJ; An G; Yi SH; Li Q; Qiu LG
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):197-204. PubMed ID: 20511165
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era.
Chen L; Fan F; Deng J; Xu J; Xu A; Sun C; Hu Y
Ann Hematol; 2019 Apr; 98(4):963-970. PubMed ID: 30610280
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN).
Liu J; Hu X; Jia Y; Lu J; Lee JH; Kim K; Chen W; Liu A; Liu Y; Chen Q; Zhang C; Suh C; Kim MK; Zhou F; Chng WJ; Kumar SK; Durie B; Hou J; Fu W; Du J
Leukemia; 2021 Jun; 35(6):1797-1802. PubMed ID: 33082513
[No Abstract] [Full Text] [Related]
[Next] [New Search]
